RaQualia Pharma Inc.
RaQualia Pharma Inc. (4579.T) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for RaQualia Pharma Inc. (4579.T), featuring income statements, balance sheets, and cash flow data.
RaQualia Pharma Inc. (4579.T) Income Statement & Financial Overview
Explore comprehensive income reports for RaQualia Pharma Inc. 4579.T, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $738.14M | $958.39M | $762.47M | $648.58M |
| Cost of Revenue | $228.91M | $169.87M | $166.45M | $105.67M |
| Gross Profit | $509.23M | $788.52M | $596.01M | $542.91M |
| Gross Profit Ratio | $0.69 | $0.82 | $0.78 | $0.84 |
| R&D Expenses | $448.78M | $422.52M | $473.65M | $359.01M |
| SG&A Expenses | $246.61M | $239.01M | $321.08M | $139.38M |
| Operating Expenses | $695.39M | $661.53M | $794.74M | $498.39M |
| Total Costs & Expenses | $924.30M | $831.40M | $961.19M | $604.07M |
| Interest Income | $0.00 | $0.00 | $776000.00 | $3.81M |
| Interest Expense | $0.00 | $0.00 | $13.90M | $1.94M |
| Depreciation & Amortization | $121.36M | $120.92M | $114.23M | $45.14M |
| EBITDA | -$64.80M | $247.91M | -$85.00M | $112.93M |
| EBITDA Ratio | -$0.09 | $0.26 | -$0.11 | $0.17 |
| Operating Income | -$186.16M | $126.99M | -$198.72M | $44.52M |
| Operating Income Ratio | -$0.25 | $0.13 | -$0.26 | $0.07 |
| Other Income/Expenses (Net) | $55.70M | -$80.52M | -$854000.00 | -$118.67M |
| Income Before Tax | -$130.46M | $46.47M | -$199.58M | -$74.16M |
| Income Before Tax Ratio | -$0.18 | $0.05 | -$0.26 | -$0.11 |
| Income Tax Expense | $24.67M | $62.50M | $46.18M | $3.95M |
| Net Income | -$155.14M | -$16.03M | -$245.75M | -$78.11M |
| Net Income Ratio | -$0.21 | -$0.02 | -$0.32 | -$0.12 |
| EPS | -$7.16 | -$0.74 | -$11.36 | -$3.61 |
| Diluted EPS | -$7.16 | -$0.74 | -$11.36 | -$3.61 |
| Weighted Avg Shares Outstanding | $21.67M | $21.64M | $21.63M | $21.62M |
| Weighted Avg Shares Outstanding (Diluted) | $21.67M | $21.64M | $21.63M | $21.62M |
Over the last four quarters, RaQualia Pharma Inc.'s revenue moved from $648.58M in Q1 2024 to $738.14M in Q4 2024. Operating income in Q4 2024 was -$186.16M, with a strong operating margin of -25%. Despite fluctuations in R&D and SG&A expenses, EBITDA for RaQualia Pharma Inc. remained robust at -$64.80M, reflecting operational efficiency. Net income dropped to -$155.14M, with an EPS of -$7.16. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan